Patents by Inventor Michael Zeppezauer
Michael Zeppezauer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9796767Abstract: The present invention provides a nucleic acid molecule which encodes a polypeptide consisting of two methionine residues as the first and second N-terminal amino acid residues linked via a peptide bond to a mature eukaryotic histone. The present invention furthermore relates to a vector containing said nucleic acid molecule, a host transformed with said vector, polypeptides encoded by the nucleic acid molecule and pharmaceutical and diagnostic compositions. The present invention also relates to the use of the nucleic acid molecule, vectors, hosts and the polypeptide of the invention for the preparation of a composition for the treatment of diseases. Furthermore, the present invention relates to a method of testing for the presence of the nucleic acid molecule or the polypeptide in a sample and to a kit.Type: GrantFiled: January 19, 2016Date of Patent: October 24, 2017Assignee: Symbiotec Genellschaft zur Erforschung auf dem Geibeit der Biotechnologie, MBHInventors: Peter Gross, Hans Jornvall, Grazyna Formicka-Zeppezauer, Michael Zeppezauer, Michel Thiry
-
Patent number: 9790259Abstract: The present invention provides a nucleic acid molecule which encodes a polypeptide consisting of two methionine residues as the first and second N-terminal amino acid residues linked via a peptide bond to a mature eukaryotic histone. The present invention furthermore relates to a vector containing said nucleic acid molecule, a host transformed with said vector, polypeptides encoded by the nucleic acid molecule and pharmaceutical and diagnostic compositions. The present invention also relates to the use of the nucleic acid molecule, vectors, hosts and the polypeptide of the invention for the preparation of a composition for the treatment of diseases. Furthermore, the present invention relates to a method of testing for the presence of the nucleic acid molecule or the polypeptide in a sample and to a kit.Type: GrantFiled: January 19, 2016Date of Patent: October 17, 2017Assignee: Symbiotec Genellschaft zur Erforschung auf dem Geibeit der Biotechnologie, MBHInventors: Peter Gross, Hans Jornvall, Grazyna Formicka-Zeppezauer, Michael Zeppezauer, Michel Thiry
-
Patent number: 9409960Abstract: The present invention provides a nucleic acid molecule which encodes a polypeptide consisting of two methionine residues as the first and second N-terminal amino acid residues linked via a peptide bond to a mature eukaryotic histone. The present invention furthermore relates to a vector containing said nucleic acid molecule, a host transformed with said vector, polypeptides encoded by the nucleic acid molecule and pharmaceutical and diagnostic compositions. The present invention also relates to the use of the nucleic acid molecule, vectors, hosts and the polypeptide of the invention for the preparation of a composition for the treatment of diseases. Furthermore, the present invention relates to a method of testing for the presence of the nucleic acid molecule or the polypeptide in a sample and to a kit.Type: GrantFiled: April 7, 2008Date of Patent: August 9, 2016Assignee: Symbiotec Gesellschaft zur Forschung und Entwicklung auf dem Gebiet der Biotechnologie mbHInventors: Peter Gross, Hans Jornvall, Grazyna Formicka-Zeppezauer, Michael Zeppezauer, Michel Thiry
-
Publication number: 20160130313Abstract: The present invention provides a nucleic acid molecule which encodes a polypeptide consisting of two methionine residues as the first and second N-terminal amino acid residues linked via a peptide bond to a mature eukaryotic histone. The present invention furthermore relates to a vector containing said nucleic acid molecule, a host transformed with said vector, polypeptides encoded by the nucleic acid molecule and pharmaceutical and diagnostic compositions. The present invention also relates to the use of the nucleic acid molecule, vectors, hosts and the polypeptide of the invention for the preparation of a composition for the treatment of diseases. Furthermore, the present invention relates to a method of testing for the presence of the nucleic acid molecule or the polypeptide in a sample and to a kit.Type: ApplicationFiled: January 19, 2016Publication date: May 12, 2016Applicant: Symbiotec Genellschaft zur Erforschung auf dem Geibeit der Biotechnologie, MBHInventors: PETER GROSS, HANS JORNVALL, GRAZYNA FORMICKA-ZEPPEZAUER, MICHAEL ZEPPEZAUER, MICHEL THIRY
-
Publication number: 20160130312Abstract: The present invention provides a nucleic acid molecule which encodes a polypeptide consisting of two methionine residues as the first and second N-terminal amino acid residues linked via a peptide bond to a mature eukaryotic histone. The present invention furthermore relates to a vector containing said nucleic acid molecule, a host transformed with said vector, polypeptides encoded by the nucleic acid molecule and pharmaceutical and diagnostic compositions. The present invention also relates to the use of the nucleic acid molecule, vectors, hosts and the polypeptide of the invention for the preparation of a composition for the treatment of diseases. Furthermore, the present invention relates to a method of testing for the presence of the nucleic acid molecule or the polypeptide in a sample and to a kit.Type: ApplicationFiled: January 19, 2016Publication date: May 12, 2016Applicant: Symbiotec Genellschaft zur Erforschung auf dem Geibeit der Biotechnologie, MBHInventors: Peter Gross, Hans Jornvall, Grazyna Formicka-Zeppezauer, Michael Zeppezauer, Michel Thiry
-
Publication number: 20150119331Abstract: The invention relates to the use of at least one human recombinant histone, especially at least one histone H1 subtype, and/or a therapeutic histone fraction as a basis for the treatment of thrombocytopenia.Type: ApplicationFiled: January 2, 2015Publication date: April 30, 2015Applicant: Symbiotec Genellschaft zur Erforshung auf dem Geibeit der Biotechnologie, MBHInventors: Michael Zeppezauer, Reiner Class
-
Patent number: 8962562Abstract: The invention relates to the use of at least one human recombinant histone, especially at least one histone H1 subtype, and/or a therapeutic histone fraction as a basis for the treatment of thrombocytopenia.Type: GrantFiled: February 4, 2013Date of Patent: February 24, 2015Assignee: Lipoxen Technologies IncorporatedInventors: Reiner Class, Michael Zeppezauer
-
Publication number: 20140315813Abstract: An active biological substance is disclosed for use in abnormal cellular and viral membrane physiologies in human and mammal organisms. The active substance has diagnostic and/or therapeutic properties and contains or consists of at least one component selected from the group of substances including: histones, covalently modified histones, histone-like polypeptides, biologically active histone sequences and histone-like polypeptides as agents for stopping the supply to solid tumours over their blood vessels, for killing cells infected by virus and for killing tumour cells with disturbed lipid asymmetry.Type: ApplicationFiled: June 10, 2014Publication date: October 23, 2014Applicant: Symbiotec Gesellschaft zur Forschung und Entwicklung auf dem Gebeit der Biotechnologie, MBHInventors: Michael Zeppezauer, Peter Gross
-
Patent number: 8778875Abstract: An active biological substance is disclosed for use in abnormal cellular and viral membrane physiologies in human and mammal organisms. The active substance has diagnostic and/or therapeutic properties and contains or consists of at least one component selected from the group of substances including: histones, covalently modified histones, histone-like polypeptides, biologically active histone sequences and histone-like polypeptides as agents for stopping the supply to solid tumors over their blood vessels, for killing cells infected by virus and for killing tumour cells with disturbed lipid asymmetry.Type: GrantFiled: August 4, 2006Date of Patent: July 15, 2014Assignee: Symbiotec Gesellschaft zur Forshung und Entwickling auf dem Gebiet der Biotechnologie, mbHInventors: Michael Zeppezauer, Peter Gross
-
Publication number: 20140148391Abstract: The invention relates to the use of at least one human recombinant histone, especially at least one histone H1 subtype, and/or a therapeutic histone fraction as a basis for the treatment of thrombocytopenia.Type: ApplicationFiled: February 4, 2013Publication date: May 29, 2014Applicant: Symbiotec Gesellschaft zur Forschung und Entwicklung auf dem Gebiet der Biotechnologie mbHInventors: Michael Zeppezauer, Reiner Class
-
Patent number: 7902146Abstract: A therapeutic or prophylactic agent for cancer is disclosed which damages the membrane and kills cancer cells, in particular of the blood-forming system, having membrane protein aggregates which contain several core histones or largely core-like histones and/or their parts. The therapeutic or prophylactic agent contains at least one pure histone or its active sequence section selected from the group composed of histone H1, H1 subtypes, H2A, H2B, H2A:H2B dimer, H3 and H4, covalent modified histones of the above-mentioned type and/or their active sections and functionally and structurally similar proteins (protamines, histone-like proteins of prokaryotic and archae bacteria).Type: GrantFiled: January 22, 2007Date of Patent: March 8, 2011Inventors: Michael Zeppezauer, Hans-Peter Leinenbach, Reiner Class, Cordula Fassbender
-
Publication number: 20110034370Abstract: The present invention provides a nucleic acid molecule which encodes a polypeptide consisting of two methionine residues as the first and second N-terminal amino acid residues linked via a peptide bond to a mature eukaryotic histone. The present invention furthermore relates to a vector containing said nucleic acid molecule, a host transformed with said vector, polypeptides encoded by the nucleic acid molecule and pharmaceutical and diagnostic compositions. The present invention also relates to the use of the nucleic acid molecule, vectors, hosts and the polypeptide of the invention for the preparation of a composition for the treatment of diseases. Furthermore, the present invention relates to a method of testing for the presence of the nucleic acid molecule or the polypeptide in a sample and to a kit.Type: ApplicationFiled: April 7, 2008Publication date: February 10, 2011Inventors: Peter Gross, Hans Jornvall, Grazyna Formicka-Zeppezauer, Michael Zeppezauer, Michel Thiry
-
Publication number: 20090305966Abstract: The invention relates to the use of at least one human recombinant histone, especially at least one histone H1 subtype, and/or a therapeutic histone fraction as a basis for the treatment of thrombocytopenia.Type: ApplicationFiled: May 4, 2006Publication date: December 10, 2009Inventors: Michael Zeppezauer, Reiner Class
-
Publication number: 20090304597Abstract: An active biological substance is disclosed for use in abnormal cellular and viral membrane physiologies in human and mammal organisms. The active substance has diagnostic and/or therapeutic properties and contains or consists of at least one component selected from the group of substances including: histones, covalently modified histones, histone-like polypeptides, biologically active histone sequences and histone-like polypeptides as agents for stopping the supply to solid tumours over their blood vessels, for killing cells infected by virus and for killing tumour cells with disturbed lipid asymmetry.Type: ApplicationFiled: August 4, 2006Publication date: December 10, 2009Applicant: SYMBIOTEC GESELLSCHAFT ZUR FORSCHUNG UND ENTWICKLUNG AUF DEM GEBIET DER BIOTECHNOLOGIE MBHInventors: Michael Zeppezauer, Peter Gross
-
Publication number: 20070203067Abstract: A therapeutic or prophylactic agent for cancer is disclosed which damages the membrane and kills cancer cells, in particular of the blood-forming system, having membrane protein aggregates which contain several core histones or largely core-like histones and/or their parts. The therapeutic or prophylactic agent contains at least one pure histone or its active sequence section selected from the group composed of histone H1, H1 subtypes, H2A, H2B, H2A:H2B dimer, H3 and H4, covalent modified histones of the above-mentioned type and/or their active sections and functionally and structurally similar proteins (protamines, histone-like proteins of prokaryotic and archae bacteria).Type: ApplicationFiled: January 22, 2007Publication date: August 30, 2007Inventors: Michael Zeppezauer, Hans-Peter Leinenbach, Reiner Class, Cordula Fassbender
-
Patent number: 6884423Abstract: The invention includes antibiotic pharmaceutical compositions comprising eukaryotic histone H1 protein and methods of using eukaryotic histone H1 protein to kill or to inhibit the growth of microorganisms, including, but not limited to, human pathogenic bacteria. The invention further includes a eukaryotic histone H1-containing animal feed and methods of improving growth of an animal by supplying the feed to the animal. The invention still further includes a kit comprising a eukaryotic histone H1-containing antibiotic pharmaceutical composition and an instructional material which describes the use of the composition. In addition, the invention includes a vaccine comprising a eukaryotic histone H1 protein and a method of vaccinating an animal using the vaccine.Type: GrantFiled: August 9, 2000Date of Patent: April 26, 2005Assignees: Symbiotec GmbH, Philadelphia Health and Education CorporationInventors: Reiner Class, Michael Zeppezauer
-
Publication number: 20030144473Abstract: Peptides are proposed with antigenic or immunogenic determinants, which result from autoantibodies in the body fluids of patients, who are suffering from autoimmun diseases, in particular diseases of the rheumatic group as systemic lupus erythematosus (SLE), rheumatoid arthritis or systemic sclerosis. In the case of the peptides it is preferably a question of the C terminus of bovine histone H1 with the sequence section 187-211 or corresponding human histon-H1-peptides of the sub-types H1.1, H1.2, H1.3, H1.4, H1.5 and H1.a and the N termini of histone H2B with the sequence sections 1-35 and 36-76, which are capable of cross reactions with the autoantibodies (anti-histone-antibodies). The invention furthermore provides ways of forming monoclonal antibodies and antiidiotypical antibodies, which are directed against autoantibodies.Type: ApplicationFiled: November 19, 2001Publication date: July 31, 2003Inventors: Michael Zeppezauer, Arno Schonberger, Ladislav Cebecauer
-
Publication number: 20030017987Abstract: A therapeutic or prophylactic agent for cancer is disclosed which damages the membrane and kills cancer cells, in particular of the blood-forming system, having membrane protein aggregates which contain several core histones or largely core-like histones and/or their parts. The therapeutic or prophylactic agent contains at least one pure histone or its active sequence section selected from the group composed of histone H1, H1 subtypes, H2A, H2B, H2A:H2B dimer, H3 and H4, covalent modified histones of the above-mentioned type and/or their active sections and functionally and structurally similar proteins (protamines, histone-like proteins of prokaryotic and archae bacteria).Type: ApplicationFiled: September 11, 2002Publication date: January 23, 2003Inventors: Michael Zeppezauer, Hans-Peter Leinenbach, Reiner Class, Cordula Fassbender
-
Patent number: 6369203Abstract: Peptides are proposed with antigenic or immunogenic determinants, which result from autoantibodies in the body fluids of patients, who are suffering from systemic lupus erythematosus (SLE). In the case of the peptides it is preferably a question of the C terminus of H1 with the sequence section 187-211 and the N termini of H2B with the sequence sections 1-35 and 36-76, which are capable of cross reactions with the autoantibodies (anti-histone-antibodies). The invention furthermore provides ways of forming monoclonal antibodies and antiidiotypical antibodies, which are directed against autoantibodies. The diagnosis of SLE is possible in accordance with the invention with a high degree of certainty and the monoclonal antibodies directed against the autoantibodies are suitable for the production of medicaments for the therapy of SLE.Type: GrantFiled: September 16, 1992Date of Patent: April 9, 2002Assignee: Symbiotec Gesellschaft zur Erforschung und Entwicklung auf dem Gebiet der Biotechnologic mbHInventors: Michael Zeppezauer, Arno Schönberger, Ladislav Cebecauer
-
Patent number: 5780432Abstract: A therapeutic method for treatment of carcinoma or autoimmune diseases of a patient, which includes administering to said patient a biologically active composition which comprises a therapeutically acceptable carrier and, in a quantity having a therapeutic effect, two active substances comprising a pure cytostatic drug as the first active substance and a biologically active pure histone selected from the group consisting of H1, H2A, H2B, H2A:H2B, and H3 as the second active substance, providing a synergistic action of both of said active substances at a site of pathogenic process of said patient.Type: GrantFiled: November 22, 1996Date of Patent: July 14, 1998Assignee: Allegheny University of the Health SciencesInventors: Michael Zeppezauer, Reiner Class